Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 6/20 | 0.34 |
| ▸ | TEAD1 | P28347 | 8/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA4 | P22748 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23278104 | 0.84 | TEAD1 (0.34) | JAK3TEAD1OPRK1CA1CA2 | |
| SCHEMBL23444394 | 0.82 | JAK3 (0.40) | JAK3OPRK1CA1CA2CA4 | |
| SCHEMBL23446088 | 0.82 | JAK3 (0.40) | JAK3OPRK1CA1CA2CA4 | |
| SCHEMBL20314946 | 0.82 | TEAD1 (0.33) | JAK3TEAD1OPRK1 | |
| SCHEMBL23323369 | 0.80 | TEAD1 (0.37) | JAK3TEAD1OPRK1CA1CA2 | |
| SCHEMBL21610084 | 0.79 | CA1 (0.49) | JAK3TEAD1OPRK1CA1CA2 | |
| SCHEMBL23444401 | 0.79 | JAK3 (0.39) | JAK3TEAD1OPRK1CA1CA2 | |
| SCHEMBL23323368 | 0.79 | JAK3 (0.35) | JAK3TEAD1BTK | |
| SCHEMBL23444404 | 0.78 | JAK3 (0.39) | JAK3TEAD1OPRK1CA1CA2 | |
| SCHEMBL23735961 | 0.78 | JAK3 (0.39) | JAK3TEAD1OPRK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | JAK3 3209/4885TEAD1 2412/4885OPRK1 4796/4885 |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | JAK3 3267/4885TEAD1 1658/4885OPRK1 4769/4885 |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | JAK3 3508/4885TEAD1 792/4885OPRK1 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.